Risk Factors Associated with Adverse Outcomes after Ablative Surgery for Lymphedema
- 26 September 2022
- journal article
- research article
- Published by Georg Thieme Verlag KG in Journal of Reconstructive Microsurgery
- Vol. 39 (03) , 214-220
Abstract
Background Postmastectomy breast cancer lymphedema poses an important health threat. Historically, physical therapy was the exclusive treatment option. More recently, lymphedema surgery has revolutionized care. As a first-in-kind, multicenter report, the postmastectomy breast cancer patients' risk factors associated with postlymphedema ablative surgical outcomes were documented. Methods Using the New York Statewide Planning and Research Cooperative System database from 2010 to 2018, multivariable models identified the postmastectomy breast cancer lymphedema surgical patients' characteristics associated with major adverse outcomes and mortality. Results Of 65,543 postmastectomy breast cancer patients, 1,052 lymphedema surgical procedures were performed including 393 (37.4%) direct excisions and 659 (63.6%) liposuctions. Direct excision and liposuction surgical patients had median ages of 58 and 52 years, respectfully (p < 0.001). Although a 30-day operative mortality was rare (0.3%, all direct excisions), major adverse outcomes occurred in 154 patients (28.5% direct excision; 6.4% liposuction; p < 0.0001). Multivariable clinical outcomes model identified that patients with higher Elixhauser's score, renal disease, emergent admissions, and direct excision surgery had higher incidences of adverse outcomes (all p < 0.01). For those patients with 30-day readmissions (n = 60), they were more likely to have undergone direct excision versus liposuction (12.5 vs. 1.7%; p < 0.0001). The important risk factors predictive of future cellulitis/lymphangitis development included diabetes mellitus, Medicaid insurance, renal disease, prior cellulitis/lymphangitis, chronic obstructive pulmonary disease (COPD), and chronic steroid use (all p < 0.01). Conclusion Lymphedema surgery carries a favorable risk profile, but better understanding the “high-risk” patients is critical. As this new era of lymphedema surgery progresses, evaluating the characteristics for adverse postoperative outcomes is an important step in our evolution of knowledge. * Both Ms. Kuruvilla and Dr. Shroyer should be considered co-first authors. ** Both Drs. Tannous and Krajewski should be considered co-last authors. Received: 17 December 2021 Accepted: 29 May 2022 Article published online: 26 September 2022 © 2022. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAKeywords
This publication has 14 references indexed in Scilit:
- A Review of Treatment for Breast Cancer-Related LymphedemaAmerican Journal of Clinical Oncology, 2018
- Current multivariate risk scores in patients undergoing non-cardiac surgery2017
- Operative Treatment of Lymphedema Using Suction-Assisted LipectomyAnnals of Plastic Surgery, 2016
- Comparison of Elixhauser and Charlson Methods for Predicting Oral Cancer SurvivalMedicine, 2016
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studiesInternational Journal of Surgery, 2014
- Trap of trends to statistical significance: likelihood of near significant P value becoming more significant with extra dataBMJ, 2014
- Applied Predictive Modeling2013
- Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative DataMedical Care, 2005
- Comorbidity Measures for Use with Administrative DataMedical Care, 1998
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987